NeuroSense Therapeutics (NRSN) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on neurodegenerative diseases: ALS, Alzheimer's, and Parkinson's.

• Lead candidate PrimeC is an oral, fixed-dose combination of ciprofloxacin and celecoxib targeting ALS via multiple disease pathways.

• PrimeC has orphan drug designation from FDA and EMA, and SME status from EMA.

• Pipeline includes additional candidates for Alzheimer's (CogniC) and Parkinson's (StabiliC), using a similar combined product strategy.

• Strong patent estate with protection for PrimeC and related formulations through at least 2042, plus expected orphan drug exclusivity.

Financial performance and metrics

• As of July 29, 2026, market value of outstanding equity held by non-affiliates was ~$24.1 million.

• Cash position as of December 31, 2025, was $166,000 (actual), $2.7 million (pro forma), and $6.4 million (pro forma as adjusted for recent offerings).

• Net tangible book value per share after the offering is estimated at $0.10, with immediate dilution of $0.38 per share to new investors.

• Company has a history of recurring losses, equity deficit, negative working capital, and negative cash flows, raising substantial doubt about its ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds will be used to advance clinical development of PrimeC for ALS, support IND applications for CogniC (AD) and StabiliC (PD), fund future R&D, and for working capital and general corporate purposes.

• Management retains broad discretion over allocation of proceeds.